Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Eshita Khera"'
Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping
Autor:
Eshita Khera, Cornelius Cilliers, Michael D. Smith, Michelle L. Ganno, Katharine C. Lai, Thomas A. Keating, Anna Kopp, Ian Nessler, Adnan O. Abu-Yousif, Greg M. Thurber
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 23, Iss 2, Pp 210-221 (2021)
With the recent approval of 3 new antibody drug conjugates (ADCs) for solid tumors, this class of drugs is gaining momentum for the targeted treatment of cancer. Despite significant investment, there are still fundamental issues that are incompletely
Externí odkaz:
https://doaj.org/article/a1d49a829b1446a5941d3e371fc652ef
Autor:
Greg M. Thurber, Richard Gregory, Jan Pinkas, Ravi Chari, Thomas A. Keating, Michael L. Miller, Yulius Setiady, Bahar Matin, Neeraj Kohli, Christopher Espelin, Olga Ab, Rassol Laleau, Eshita Khera, Leanne Lanieri, Jose F. Ponte
Supplementary figures and data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::633ee436ae1eb2f1537f2ada328961b9
https://doi.org/10.1158/1535-7163.22521463
https://doi.org/10.1158/1535-7163.22521463
Autor:
Greg M. Thurber, Floris L. van Delft, Laureen de Bever, Haolong Huang, Shujun Dong, Eshita Khera
Supplementary DataSupplementary Fig. S1-S21, Table S1-S5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6e26f9132e8c3cde6ea63db11e3e351
https://doi.org/10.1158/1535-7163.22522801
https://doi.org/10.1158/1535-7163.22522801
Autor:
Greg M. Thurber, Normann Goodwin, Lorraine Thompson, James Legg, Thomas Sandal, Adnan O. Abu-Yousif, Thomas A. Keating, Qifeng Qiu, Anna Kopp, Steven Vance, Eshita Khera, Ian Nessler
Targeted delivery of chemotherapeutics aims to increase efficacy and lower toxicity by concentrating drugs at the site-of-action, a method embodied by the seven current FDA-approved antibody–drug conjugates (ADC). However, a variety of pharmacokine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04bb7ab2805dd13cdbb4ee95f79492b5
https://doi.org/10.1158/0008-5472.c.6511984.v1
https://doi.org/10.1158/0008-5472.c.6511984.v1
Autor:
Eshita Khera, Shujun Dong, Haolong Huang, Laureen de Bever, Floris L. van Delft, Greg M. Thurber
Publikováno v:
Molecular Cancer Therapeutics. 21:310-321
After several notable clinical failures in early generations, antibody–drug conjugates (ADC) have made significant gains with seven new FDA approvals within the last 3 years. These successes have been driven by a shift towards mechanistically infor
Autor:
Bruna Menezes, Eshita Khera, Melissa Calopiz, Michael D. Smith, Michelle L. Ganno, Cornelius Cilliers, Adnan O. Abu-Yousif, Jennifer J. Linderman, Greg M. Thurber
Publikováno v:
The AAPS journal. 24(6)
The development of new antibody-drug conjugates (ADCs) has led to the approval of 7 ADCs by the FDA in 4 years. Given the impact of intratumoral distribution on efficacy of these therapeutics, coadministration of unconjugated antibody with ADC has be
Mechanistically weighted metric to predictin vivoantibody-receptor occupancy: An analytical approach
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. :JPET-AR
Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping
Autor:
Katharine C. Lai, Michael D. Smith, Ian Nessler, Anna Kopp, Cornelius Cilliers, Thomas A. Keating, Adnan O. Abu-Yousif, Greg M. Thurber, Michelle L. Ganno, Eshita Khera
Publikováno v:
Neoplasia (New York, N.Y.)
Neoplasia: An International Journal for Oncology Research, Vol 23, Iss 2, Pp 210-221 (2021)
Neoplasia: An International Journal for Oncology Research, Vol 23, Iss 2, Pp 210-221 (2021)
With the recent approval of 3 new antibody drug conjugates (ADCs) for solid tumors, this class of drugs is gaining momentum for the targeted treatment of cancer. Despite significant investment, there are still fundamental issues that are incompletely
Autor:
Thomas Sandal, Ian Nessler, Steven Vance, Thomas A. Keating, Anna Kopp, Lorraine Thompson, Eshita Khera, Adnan O. Abu-Yousif, Qifeng Qiu, Greg M. Thurber, Normann Goodwin, James Legg
Publikováno v:
Cancer Research. 80:1268-1278
Targeted delivery of chemotherapeutics aims to increase efficacy and lower toxicity by concentrating drugs at the site-of-action, a method embodied by the seven current FDA-approved antibody–drug conjugates (ADC). However, a variety of pharmacokine
Autor:
Christopher W. Espelin, Michael L. Miller, Richard J. Gregory, Ravi V. J. Chari, Thomas A. Keating, Leanne Lanieri, Jan Pinkas, Eshita Khera, Neeraj Kohli, Bahar Matin, Olga Ab, Yulius Setiady, Greg M. Thurber, Rassol Laleau, Jose F. Ponte
Publikováno v:
Mol Cancer Ther
Several antibody–drug conjugates (ADC) showing strong clinical responses in solid tumors target high expression antigens (HER2, TROP2, Nectin-4, and folate receptor alpha/FRα). Highly expressed tumor antigens often have significant low-level expre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d2e301f9d9125eef2ded1e3c0cffdd9
https://europepmc.org/articles/PMC7790875/
https://europepmc.org/articles/PMC7790875/